Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 20,548
Companies: 1,769
Drugs tracked: 4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

zelicapavir

zinc supplementation

1 Nalmefene implant

1 mg/kg GR-MD-02

100U inactivated Enterovirus Type 71 Vaccine

11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

131I-apamistmab

14028 injection

15NH4Cl, Sodium Chloride for injection, [13C]Sodium Acetate, CMP-CPS-001

15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

304 injection

9MW3811 injection

9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS120, which is an Antibody medication, to be administered alone or with Pembrolizumab in Subjects with Advanced Malignancies

A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced Malignancies

A First-in-Human, randomised, double blind, placebo-controlled, single ascending dose trial to evaluate safety, tolerability, and pharmacokinetics of APC148 in healthy adults.

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients with Selected Advanced Solid Tumors

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors

A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

A Phase 1 Study of JNJ-88549968, a T-cell Redirecting Antibody, for CALR-mutated Myeloproliferative Neoplasms

Frequently asked questions